ClinicalTrials.gg
CompletedNCT03371797ALERTUpdated Nov 8, 2018

Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial

An observational study in Essential Hypertension, sponsored by PharmEvo Pvt Ltd. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-08.

Sponsored by PharmEvo Pvt Ltd · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
800
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.

Read the detailed description

Avsar in tablet form which contains two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland International studies are available concerning the single pill combination therapy used in Blood pressure reduction. To determine the clinical significance of single pill combination, conducted multi center real life study i.e.; "ALERT Trial" in our local population. Through this study, observed the effect of single pill combination on BP reduction and adverse events in health care settings. Antihypertensive drugs use in a single pill combination may further enhance BP control by reducing pill burden and improve patient compliance.

02

Conditions studied

  • Essential Hypertension

Keywords

  • ALERT, MSSBP, MSDBP
03

In context

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 800 is above the median of 718 across 71 observational studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

PharmEvo Pvt Ltd is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Ages Eligible for Study: 18 years - 70 Years Genders Eligible for Study: Both

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient whose BP is >139/89mmHg and on monotherapy with minimum last 30 days
  • Male or female aged (18 years - 70 Years)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Secondary Hypertension
  • Pregnant or Lactating mother
  • to any active ingredient
  • Peripheral artery disease
  • Hepatic disease or biliary tract obstruction
  • Chronic kidney disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
800 participants (actual)
Patient registry
No

Groups and cohorts

  • Treatment group

    Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.

    Drug: Valsartan, Amlodipine -

Interventions

  • DrugValsartan, Amlodipine -

    Drug pages: Valsartan · Amlodipine

    Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent. Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker.

    Also known as: AVSAR

06

What researchers measure

Primary outcomes

  1. Efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure after 8 weeks of therapy.

    To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) after 8 weeks of therapy. \[Designated as safety issue: No\]

    Time frame: 8 weeks

Secondary outcomes

  1. Measure percentage of participant with blood pressure change of <139/89 mmHg at the end of 8 week

    To measure percentage of participant with blood pressure change of \<139/89 mmHg at the end of 8 week \[Designated as safety issue: No\]

    Time frame: 8 weeks

  2. Participants experiencing adverse effect after taking single pill combination

    Proportion of participants experiencing adverse effect after taking single pill combination \[Designated as safety issue: Yes\]

    Time frame: 8 weeks

07

Study locations

1 site
  • Medicell
    Karachi, Sindh 75290, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2018, 7 months.

Of 27 observational studies under Essential Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 52. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 13, 2017
StartActual
Feb 20, 2018
Primary completionActual
Oct 1, 2018
CompletionActual
Nov 5, 2018
Last update
Nov 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03371797
Lead sponsor
PharmEvo Pvt Ltd
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Feb 20, 2018
Primary completion
Oct 1, 2018
Completion
Nov 5, 2018
Last update
Nov 8, 2018

Study contacts

Tasneem Ahsan, MBBS
principal investigator · PharmEvo Pvt Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion